Cancer

ALA shows it can scale: Pathway towards an “off the shelf” cancer treatment

Next Investors Apr 17, 2023

This morning Arovella Therapeutics (ASX: ALA) released new data indicating its treatment, ALA-101, has the potential to be a novel, ‘off the shelf’ cell therapy to treat leukemias and lymphomas.

$1.5M annual cost savings allows ALA to focus on what really matters

Next Investors Oct 28, 2022

Arovella Therapeutics (ASX:ALA) announced on Wednesday that it had decided to phase out its legacy operations to fully focus on its CAR iNKT treatment for cancer.

$23M capped ALA partners with $1.1BN Imugene - Now Targeting 90% of Cancers

Next Investors Sep 27, 2022

Yesterday, Arovella Therapeutics (ASX:ALA) announced that it had signed a partnership agreement with $1.1BN capped Imugene to develop its technology to target solid tumour cancer cells.

Pre-result build up? The “big catalyst” in 2023

Finfeed Sep 02, 2022

Our biotech Investment and 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), has been busy this year working towards its all important Phase 3 trial and first interim results. After our initial entry at 20c in August 2021, our Investment in DXB is currently sitting below that price at 14.5 cents.

PharmAust's phase II monepantel trials a success

Finfeed Archived May 12, 2020

PharmAust (ASX: PAA) has released promising data in relation to its monepantel canine trial, investigating the anti-cancer effects of monepantel tablets in dogs.

OncoSil on verge of CE Mark approval

Finfeed Archived Feb 27, 2020

The coming 12 months is shaping up as a watershed stage in the history of Oncosil Medical Ltd (ASX:OSL) as it flags the finalisation of commercialisation plans for its OncoSil™ device ahead of CE marking early in 2020.

Epichem contract to boost revenues at PharmAust

Finfeed Archived Jan 08, 2020

PharmAust Limited’s (ASX:PAA) wholly-owned subsidiary, Epichem Pty Ltd, has been awarded an extension to its current contract with Drugs for Neglected Diseases initiative.

Childhood cancer research gets million dollar boost

Finfeed Archived Dec 16, 2019

Australian Lions Childhood Cancer Research Foundation has announced it will provide $1.05 million of funding to the Telethon Kids Institute.

PharmAust Expands Site Recruitment for Phase II Pet Dog Cancer Trial

Finfeed Archived Dec 11, 2019

PharmAust Ltd (ASX:PAA), a clinical-stage oncology company that’s developing targeted cancer therapeutics for humans and animals, reports that it has expanded site recruitment for its anti-cancer trial in pet dogs with treatment naïve B cell lymphoma.

Page 1 of 7 next >